Published in Lab Business Week, July 12th, 2009
Even in times of economic prosperity, the pharmaceutical industry has often been reluctant to get involved in developing treatments for diseases that occur primarily in low income countries. The low cost D3 approach, involving distributed global educational resources at the early stage of discovery, is even more attractive in this time of global economic downturn.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week